Alpine
is a Washington-based biotechnology company that researches and develops protein-based immunotherapies for the treatment of cancer and autoimmune diseases... Read moreAlpine
is a Washington-based biotechnology company that researches and develops protein-based immunotherapies for the treatment of cancer and autoimmune diseases... Read more
CEO
Mitchell H. Gold
News
Dec 29, 2024
Pharamceutical Technology
Alpine: Povetacicept by Alpine Immune Sciences for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval
May 10, 2024
Markets Insider
Alpine: Alpine Immune Sciences GAAP EPS of -$0.28 beats by $0.12, revenue of $7.03M beats by
May 10, 2024
Owler
Alpine Immune Sciences, Inc.: Alpine's revenue changed from $58.88M in Dec 2023 to $56.52M in Mar 2024
May 09, 2024
Business Wire
Press Release: Alpine : Alpine Immune Sciences Reports First Quarter 2024 Financial Results
Apr 19, 2024
Endpoints News
Alpine: Vertex, Alpine's IgAN drug has Humira-like potential. But not all indications are created equal
Apr 17, 2024
MarketScreener
Alpine: INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN
Apr 15, 2024
Pharmaceutical Processing World
Alpine: Vertex Pharmaceuticals to acquire Alpine Immune Sciences in $4.9B deal
Apr 12, 2024
Zacks
Alpine: Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Apr 12, 2024
Seeking Alpha
Alpine: Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement
Apr 11, 2024
Benzinga
Alpine: Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Alpine Competitors
1
2
3
4
5
6
7
8
9
10